

DAY PROGRAMME

19 May 2017 (Friday)

Time	Programme		
09:00 – 09:30	Registration		
09:30 – 11:00	<p>Plenary Lecture 1: Basic Sciences <i>Chairpersons: X.Y. GUAN (Hong Kong), Tak-wah MAK (Canada)</i></p> <p>Beyond Oncogenes: Emerging Strategies in Anti-cancer Targets Tak-wah MAK (Canada)</p> <p>Whole-exome Sequencing-identified Macrophage-stimulating Receptor 1 (MST1R) in NPC Genetic Susceptibility Maria LUNG (Hong Kong)</p> <p>Hepatocellular Carcinoma Treatment at the Intersection between Antiangiogenic Therapy and Immunotherapy Dan G. DUDA (USA)</p> <p style="text-align: right;">Salon 5-6</p>		
11:00 – 11:30	Coffee Tea Break & Exhibition		
11:30 – 12:45	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 1: Sarcoma <i>Chairpersons: Ying-lee LAM (Hong Kong), Tony Wai-hung SHEK (Hong Kong)</i></p> <p>Excision of Soft Tissue Sarcoma: Preoperative Planning Ying-lee LAM (Hong Kong)</p> <p>Advances of Radiation Oncology in the Management of Soft Tissue Sarcoma Brian O'SULLIVAN (Canada)</p> <p>An Update and Concise Guide to Sarcomas Robin JONES (UK)</p> <p style="text-align: right;">Salon 5-6</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 2: Drug Development in Oncology <i>Chairperson: Lilian SIU (Canada)</i></p> <p>Early Phase Clinical Trials in the Era of Immunotherapy Lilian SIU (Canada)</p> <p>The Challenges and Opportunities of Early Clinical Trials in Hong Kong Joanne CHIU (Hong Kong)</p> <p>Early Phase Clinical Trials in the Era of Genomic Medicine Timothy YAP (USA)</p> <p style="text-align: right;">Salon 1-4</p> </td> </tr> </table>	<p>Concurrent Session 1: Sarcoma <i>Chairpersons: Ying-lee LAM (Hong Kong), Tony Wai-hung SHEK (Hong Kong)</i></p> <p>Excision of Soft Tissue Sarcoma: Preoperative Planning Ying-lee LAM (Hong Kong)</p> <p>Advances of Radiation Oncology in the Management of Soft Tissue Sarcoma Brian O'SULLIVAN (Canada)</p> <p>An Update and Concise Guide to Sarcomas Robin JONES (UK)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 2: Drug Development in Oncology <i>Chairperson: Lilian SIU (Canada)</i></p> <p>Early Phase Clinical Trials in the Era of Immunotherapy Lilian SIU (Canada)</p> <p>The Challenges and Opportunities of Early Clinical Trials in Hong Kong Joanne CHIU (Hong Kong)</p> <p>Early Phase Clinical Trials in the Era of Genomic Medicine Timothy YAP (USA)</p> <p style="text-align: right;">Salon 1-4</p>
<p>Concurrent Session 1: Sarcoma <i>Chairpersons: Ying-lee LAM (Hong Kong), Tony Wai-hung SHEK (Hong Kong)</i></p> <p>Excision of Soft Tissue Sarcoma: Preoperative Planning Ying-lee LAM (Hong Kong)</p> <p>Advances of Radiation Oncology in the Management of Soft Tissue Sarcoma Brian O'SULLIVAN (Canada)</p> <p>An Update and Concise Guide to Sarcomas Robin JONES (UK)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 2: Drug Development in Oncology <i>Chairperson: Lilian SIU (Canada)</i></p> <p>Early Phase Clinical Trials in the Era of Immunotherapy Lilian SIU (Canada)</p> <p>The Challenges and Opportunities of Early Clinical Trials in Hong Kong Joanne CHIU (Hong Kong)</p> <p>Early Phase Clinical Trials in the Era of Genomic Medicine Timothy YAP (USA)</p> <p style="text-align: right;">Salon 1-4</p>		
12:45 – 14:15	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Lunch Symposium (Sponsored by Amgen) <i>Chairperson: Chi-leung CHIANG (Hong Kong)</i></p> <p>Optimizing Treatment Outcomes in Metastatic Colorectal Cancer Niall TEBBUTT (Australia)</p> <p>Anti-EGFR Therapy: the Right Patient at the Right Time Ka-on LAM (Hong Kong)</p> <p style="text-align: right;">Salon 5-6</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Lunch Symposium (Sponsored by BMS) <i>Chairpersons: Thomas YAU (Hong Kong), Roger NGAN (Hong Kong)</i></p> <p>Emerging Treatment in Recurrent/Metastatic Head and Neck Cancers: A Changing Landscape with Potential to Impact on Primary Treatment of Locally Advanced Disease Kevin HARRINGTON (UK)</p> <p>Management of Advanced Hepatocellular Carcinoma: At the Dawn of a New Era Thomas YAU (Hong Kong)</p> <p style="text-align: right;">Salon 1-4</p> </td> </tr> </table>	<p>Lunch Symposium (Sponsored by Amgen) <i>Chairperson: Chi-leung CHIANG (Hong Kong)</i></p> <p>Optimizing Treatment Outcomes in Metastatic Colorectal Cancer Niall TEBBUTT (Australia)</p> <p>Anti-EGFR Therapy: the Right Patient at the Right Time Ka-on LAM (Hong Kong)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Lunch Symposium (Sponsored by BMS) <i>Chairpersons: Thomas YAU (Hong Kong), Roger NGAN (Hong Kong)</i></p> <p>Emerging Treatment in Recurrent/Metastatic Head and Neck Cancers: A Changing Landscape with Potential to Impact on Primary Treatment of Locally Advanced Disease Kevin HARRINGTON (UK)</p> <p>Management of Advanced Hepatocellular Carcinoma: At the Dawn of a New Era Thomas YAU (Hong Kong)</p> <p style="text-align: right;">Salon 1-4</p>
<p>Lunch Symposium (Sponsored by Amgen) <i>Chairperson: Chi-leung CHIANG (Hong Kong)</i></p> <p>Optimizing Treatment Outcomes in Metastatic Colorectal Cancer Niall TEBBUTT (Australia)</p> <p>Anti-EGFR Therapy: the Right Patient at the Right Time Ka-on LAM (Hong Kong)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Lunch Symposium (Sponsored by BMS) <i>Chairpersons: Thomas YAU (Hong Kong), Roger NGAN (Hong Kong)</i></p> <p>Emerging Treatment in Recurrent/Metastatic Head and Neck Cancers: A Changing Landscape with Potential to Impact on Primary Treatment of Locally Advanced Disease Kevin HARRINGTON (UK)</p> <p>Management of Advanced Hepatocellular Carcinoma: At the Dawn of a New Era Thomas YAU (Hong Kong)</p> <p style="text-align: right;">Salon 1-4</p>		
14:15 – 15:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 3: Hepatocellular Cancer <i>Chairpersons: Tan-to CHEUNG (Hong Kong), Masatoshi KUDO (Japan)</i></p> <p>Role of SBRT for the Management of HCC Laura DAWSON (Canada)</p> <p>The Role of Radioembolization in the Management of HCC Pierce Kah-hoe CHOW (Singapore)</p> <p>Latest Advances in Using Molecular Targeted Therapy in Advanced HCC Patients Masatoshi KUDO (Japan)</p> <p style="text-align: right;">Salon 5-6</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 4: Neuroendocrine Tumour <i>Chairpersons: Foon-yiu CHEUNG (Hong Kong), Roland LEUNG (Hong Kong)</i></p> <p>Update on Pathology of Neuroendocrine Tumors (NET) of the GI Tract Tony Wai-hung SHEK (Hong Kong)</p> <p>Progress in the Land of Small Tumours: Recent Advances and Future Directions in Advanced Neuroendocrine Tumours James YAO (USA)</p> <p>Use of Peptide Receptor Radionuclide Therapy (PPRT) for Treatment of Neuroendocrine Tumour Thomas Kam-chau CHENG (Hong Kong)</p> <p style="text-align: right;">Salon 1-4</p> </td> </tr> </table>	<p>Concurrent Session 3: Hepatocellular Cancer <i>Chairpersons: Tan-to CHEUNG (Hong Kong), Masatoshi KUDO (Japan)</i></p> <p>Role of SBRT for the Management of HCC Laura DAWSON (Canada)</p> <p>The Role of Radioembolization in the Management of HCC Pierce Kah-hoe CHOW (Singapore)</p> <p>Latest Advances in Using Molecular Targeted Therapy in Advanced HCC Patients Masatoshi KUDO (Japan)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 4: Neuroendocrine Tumour <i>Chairpersons: Foon-yiu CHEUNG (Hong Kong), Roland LEUNG (Hong Kong)</i></p> <p>Update on Pathology of Neuroendocrine Tumors (NET) of the GI Tract Tony Wai-hung SHEK (Hong Kong)</p> <p>Progress in the Land of Small Tumours: Recent Advances and Future Directions in Advanced Neuroendocrine Tumours James YAO (USA)</p> <p>Use of Peptide Receptor Radionuclide Therapy (PPRT) for Treatment of Neuroendocrine Tumour Thomas Kam-chau CHENG (Hong Kong)</p> <p style="text-align: right;">Salon 1-4</p>
<p>Concurrent Session 3: Hepatocellular Cancer <i>Chairpersons: Tan-to CHEUNG (Hong Kong), Masatoshi KUDO (Japan)</i></p> <p>Role of SBRT for the Management of HCC Laura DAWSON (Canada)</p> <p>The Role of Radioembolization in the Management of HCC Pierce Kah-hoe CHOW (Singapore)</p> <p>Latest Advances in Using Molecular Targeted Therapy in Advanced HCC Patients Masatoshi KUDO (Japan)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 4: Neuroendocrine Tumour <i>Chairpersons: Foon-yiu CHEUNG (Hong Kong), Roland LEUNG (Hong Kong)</i></p> <p>Update on Pathology of Neuroendocrine Tumors (NET) of the GI Tract Tony Wai-hung SHEK (Hong Kong)</p> <p>Progress in the Land of Small Tumours: Recent Advances and Future Directions in Advanced Neuroendocrine Tumours James YAO (USA)</p> <p>Use of Peptide Receptor Radionuclide Therapy (PPRT) for Treatment of Neuroendocrine Tumour Thomas Kam-chau CHENG (Hong Kong)</p> <p style="text-align: right;">Salon 1-4</p>		
15:30 – 16:00	Coffee Tea Break & Exhibition		
16:00 – 16:30	<p>Opening Ceremony</p> <p style="text-align: right;">Salon 5-6</p>		
16:30 – 18:30	<p>Plenary Lecture 2: Precision Medicine <i>Chairpersons: Victor LEE (Hong Kong), Irene NG (Hong Kong)</i></p> <p>Personalized Medicine in Novel Clinical Candidates in Metabolic Pathways Tak-wah MAK (Canada)</p> <p>Advanced Melanoma in 2017: Immunotherapy vs. Targeted Therapy Victoria ATKINSON (Australia)</p> <p>Pan Histology Development of Targeted Therapies and Impact on Oncology Practice Steven Potts (USA)</p> <p>Management of Advanced Lung Cancer in the Era of Precision Medicine Corey J. LANGER (USA)</p> <p style="text-align: right;">Salon 5-6</p>		
18:30 – 19:45	<p>Satellite Symposium (Sponsored by Roche) <i>Chairperson: James HO (Hong Kong), Victor LEE (Hong Kong)</i></p> <p>Updates on Cancer Immunotherapy (CIT) in Advanced NSCLC Kenneth O'BYRNE (Australia)</p> <p>PD-L1 Inhibition in Advanced NSCLC in Real-world Setting Ross SOO (Singapore)</p> <p style="text-align: right;">Salon 5-6</p>		
19:45 -	<p>Gala Dinner (Sponsored by Roche)</p> <p style="text-align: right;">Salon 1-4</p>		

DAY PROGRAMME

20 May 2017 (Saturday)

Time	Programme		
08:00 – 08:30	Registration		
08:30 – 10:30	<p>Plenary Lecture 3: Renaissance of Immuno-Oncology in Cancer Treatment (Sponsored by MSD) Chairpersons: Han-chong TOH (Singapore), Thomas YAU (Hong Kong)</p> <p>Tumour Heterogeneity and Immune Surveillance Charles SWANTON (UK)</p> <p>Immune Checkpoint Inhibitors in NSCLC: Now and Future Corey J. LANGER (USA)</p> <p>Role of Biomarker in NSCLC in the Era of Immuno-Oncology Rina HUI (Australia)</p> <p>The Role of Immunotherapy in Gastrointestinal Cancer Dung Thi LE (USA)</p> <p style="text-align: right;">Salon 5-6</p>		
10:30 – 10:50	Coffee Tea Break & Exhibition (Sponsored by AstraZeneca)		
10:50 – 12:05	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 5: Clinical Oncology Chairpersons: Amy CHANG (Hong Kong), Dora KWONG (Hong Kong)</p> <p>Treatment of Non-small Cell Lung Cancer Patients with Uncommon Driver Mutations James Chih-hsin YANG (Taiwan)</p> <p>Recent Advances of SBRT for Hepatocellular Carcinoma Jinsil SEONG (South Korea)</p> <p>Combinatorial Immune Therapies to Enhance Outcomes in Solid Cancers Kevin HARRINGTON (UK)</p> <p style="text-align: right;">Salon 5-6</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 6: Haematology Chairperson: Yok-lam KWONG (Hong Kong)</p> <p>Novel Treatment Strategies in ALL: The Evolving Role of Immunotherapy David RITCHIE (Australia) (Sponsored by Amgen)</p> <p>Checkpoint Inhibition Where Do We Go from Here Yok-lam KWONG (Hong Kong)</p> <p>Immunotherapy: Changing the Landscape from Hodgkin to NK/T-cell Lymphoma Daryl TAN (Singapore) (Sponsored by MSD)</p> <p style="text-align: right;">Salon 1-4</p> </td> </tr> </table>	<p>Concurrent Session 5: Clinical Oncology Chairpersons: Amy CHANG (Hong Kong), Dora KWONG (Hong Kong)</p> <p>Treatment of Non-small Cell Lung Cancer Patients with Uncommon Driver Mutations James Chih-hsin YANG (Taiwan)</p> <p>Recent Advances of SBRT for Hepatocellular Carcinoma Jinsil SEONG (South Korea)</p> <p>Combinatorial Immune Therapies to Enhance Outcomes in Solid Cancers Kevin HARRINGTON (UK)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 6: Haematology Chairperson: Yok-lam KWONG (Hong Kong)</p> <p>Novel Treatment Strategies in ALL: The Evolving Role of Immunotherapy David RITCHIE (Australia) (Sponsored by Amgen)</p> <p>Checkpoint Inhibition Where Do We Go from Here Yok-lam KWONG (Hong Kong)</p> <p>Immunotherapy: Changing the Landscape from Hodgkin to NK/T-cell Lymphoma Daryl TAN (Singapore) (Sponsored by MSD)</p> <p style="text-align: right;">Salon 1-4</p>
<p>Concurrent Session 5: Clinical Oncology Chairpersons: Amy CHANG (Hong Kong), Dora KWONG (Hong Kong)</p> <p>Treatment of Non-small Cell Lung Cancer Patients with Uncommon Driver Mutations James Chih-hsin YANG (Taiwan)</p> <p>Recent Advances of SBRT for Hepatocellular Carcinoma Jinsil SEONG (South Korea)</p> <p>Combinatorial Immune Therapies to Enhance Outcomes in Solid Cancers Kevin HARRINGTON (UK)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 6: Haematology Chairperson: Yok-lam KWONG (Hong Kong)</p> <p>Novel Treatment Strategies in ALL: The Evolving Role of Immunotherapy David RITCHIE (Australia) (Sponsored by Amgen)</p> <p>Checkpoint Inhibition Where Do We Go from Here Yok-lam KWONG (Hong Kong)</p> <p>Immunotherapy: Changing the Landscape from Hodgkin to NK/T-cell Lymphoma Daryl TAN (Singapore) (Sponsored by MSD)</p> <p style="text-align: right;">Salon 1-4</p>		
12:05 – 13:30	<p>Lunch Symposium: A New Era in Cancer Management (Sponsored by MSD) Chairperson: Thomas YAU (Hong Kong)</p> <p>Advancement in Immunotherapy for Head & Neck Cancer Lillian SIU (Canada)</p> <p>Immune Checkpoint Inhibitors: New Treatment in Bladder Cancer Ravindran KANESVARAN (Singapore)</p> <p>Breakthrough Therapy in MSI-H Colorectal and Other Cancers Dung Thi LE (USA)</p> <p style="text-align: right;">Salon 5-6</p>		
13:30 – 14:40	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 7: GI Oncology Chairpersons: Ka-on LAM (Hong Kong), Yim-kwan LAM (Hong Kong)</p> <p>Does Harnessing the Immune System Against Colorectal Cancer Work Han-chong TOH (Singapore)</p> <p>Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer Victor LEE (Hong Kong)</p> <p>What Have We Learned from Recent Major Clinical Trials for the Management of GEP-NET? Christos TOUMPANAKIS (UK) (Sponsored by Ipsen)</p> <p style="text-align: right;">Salon 5-6</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Concurrent Session 8: Gynae Oncology Chairpersons: Karen CHAN (Hong Kong), Bradley J. MONK (USA)</p> <p>Targeted Therapy in Cervical Cancer Bradley J. MONK (USA)</p> <p>Primary Debulking Surgery (PDS) vs Interval Debulking Surgery (IDS): This is the Question for More Than 20 Years in the Surgical Management of Advanced Ovarian Cancer Sang-Yoon PARK (South Korea)</p> <p>Molecular Profiling of Ovarian Cancers to Optimize Therapy David TAN (Singapore)</p> <p style="text-align: right;">Salon 1-4</p> </td> </tr> </table>	<p>Concurrent Session 7: GI Oncology Chairpersons: Ka-on LAM (Hong Kong), Yim-kwan LAM (Hong Kong)</p> <p>Does Harnessing the Immune System Against Colorectal Cancer Work Han-chong TOH (Singapore)</p> <p>Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer Victor LEE (Hong Kong)</p> <p>What Have We Learned from Recent Major Clinical Trials for the Management of GEP-NET? Christos TOUMPANAKIS (UK) (Sponsored by Ipsen)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 8: Gynae Oncology Chairpersons: Karen CHAN (Hong Kong), Bradley J. MONK (USA)</p> <p>Targeted Therapy in Cervical Cancer Bradley J. MONK (USA)</p> <p>Primary Debulking Surgery (PDS) vs Interval Debulking Surgery (IDS): This is the Question for More Than 20 Years in the Surgical Management of Advanced Ovarian Cancer Sang-Yoon PARK (South Korea)</p> <p>Molecular Profiling of Ovarian Cancers to Optimize Therapy David TAN (Singapore)</p> <p style="text-align: right;">Salon 1-4</p>
<p>Concurrent Session 7: GI Oncology Chairpersons: Ka-on LAM (Hong Kong), Yim-kwan LAM (Hong Kong)</p> <p>Does Harnessing the Immune System Against Colorectal Cancer Work Han-chong TOH (Singapore)</p> <p>Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer Victor LEE (Hong Kong)</p> <p>What Have We Learned from Recent Major Clinical Trials for the Management of GEP-NET? Christos TOUMPANAKIS (UK) (Sponsored by Ipsen)</p> <p style="text-align: right;">Salon 5-6</p>	<p>Concurrent Session 8: Gynae Oncology Chairpersons: Karen CHAN (Hong Kong), Bradley J. MONK (USA)</p> <p>Targeted Therapy in Cervical Cancer Bradley J. MONK (USA)</p> <p>Primary Debulking Surgery (PDS) vs Interval Debulking Surgery (IDS): This is the Question for More Than 20 Years in the Surgical Management of Advanced Ovarian Cancer Sang-Yoon PARK (South Korea)</p> <p>Molecular Profiling of Ovarian Cancers to Optimize Therapy David TAN (Singapore)</p> <p style="text-align: right;">Salon 1-4</p>		
14:40 – 15:00	Coffee Tea Break & Exhibition (Sponsored by Eli Lilly)		
15:00 – 17:00	<p>Plenary Lecture 4: Advances in Global Oncology Practice Chairpersons: Joanne CHIU (Hong Kong), Gilberto de Lima LOPES, Jr (USA)</p> <p>What is Global Oncology? Gilberto de Lima LOPES, Jr (USA)</p> <p>Essential Pillars to Advance Oncology Practice Brian O'SULLIVAN (Canada)</p> <p>Renal Cell Cancer: Present and Future Bernard ESCUDIER (France)</p> <p>The Development of CDK 4/6 Inhibitors: From Bench to Clinic Richard FINN (USA)</p> <p style="text-align: right;">Salon 5-6</p>		
17:00	<p>Closing Ceremony</p> <p style="text-align: right;">Salon 5-6</p>		

The programme is subject to change without prior notice.